Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Nature Genetics

Volumn 44, Issue 10, 2012, Pages 1111-1116

  Rudin, Charles M ^a   Durinck, Steffen ^b,c   Stawiski, Eric W ^b,c   Poirier, John T ^a   Modrusan, Zora ^b   Shames, David S ^c   Bergbower, Emily A ^a   Guan, Yinghui ^b   Shin, James ^a   Guillory, Joseph ^b   Rivers, Celina Sanchez ^b   Foo, Catherine K ^b   Bhatt, Deepali ^b   Stinson, Jeremy ^b   Gnad, Florian ^c   Haverty, Peter M ^c   Gentleman, Robert ^c   Chaudhuri, Subhra ^b   Janakiraman, Vasantharajan ^b   Jaiswal, Bijay S ^b   Parikh, Chaitali ^b   Yuan, Wenlin ^b   Zhang, Zemin ^c   Koeppen, Hartmut ^c   Wu, Thomas D ^c   Stern, Howard M ^c   Yauch, Robert L ^c   Huffman, Kenneth E ^d   Paskulin, Diego D ^e   Illei, Peter B ^a   Varella Garcia, Marileila ^e   Gazdar, Adi F ^d   De Sauvage, Frederic J ^b   Bourgon, Richard ^c   Minna, John D ^d   Brock, Malcolm V ^a   Seshagiri, Somasekar ^b   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

^c Department of Bioinformatics and Computational Biology ^*  (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN MODIFYING PROTEIN; G PROTEIN COUPLED RECEPTOR; PHOSPHOTRANSFERASE; PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; FUSION GENE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; GENE INSERTION; GENE MUTATION; GENE SILENCING; GENETIC CODE; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INDEL MUTATION; LUNG SMALL CELL CANCER; LYMPHOBLASTOID CELL; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; RLF MYCL1 FUSION GENE; RNA SEQUENCE; SOX2 GENE; SPLICING DEFECT;

BASE SEQUENCE; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; EXOME; GENE AMPLIFICATION; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN KINASES; SMALL CELL LUNG CARCINOMA; SOXB1 TRANSCRIPTION FACTORS;

EID: 84866849548     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2405     Document Type: Article

References (48)

1. Siegel, R., Ward, E., Brawley, O. & Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61, 212-236 (2011).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
3. Hann, C.L. & Rudin, C.M. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends Mol. Med. 13, 150-157 (2007).
4. Wistuba, I.I., Gazdar, A.F. & Minna, J.D. Molecular genetics of small cell lung carcinoma. Semin. Oncol. 28, 3-13 (2001).
5. Mori, N. et al. Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 5, 1713-1717 (1990).
6. Arriola, E. et al. Genetic changes in small cell lung carcinoma. Clin. Transl. Oncol. 10, 189-197 (2008).
7. Yokomizo, A. et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17, 475-479 (1998).
8. Tatematsu, A. et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin. Cancer Res. 14, 6092-6096 (2008).
9. Shibata, T., Kokubu, A., Tsuta, K. & Hirohashi, S. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett. 283, 203-211 (2009).
10. Onuki, N. et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85, 600-607 (1999).
11. Sher, T., Dy, G.K. & Adjei, A.A. Small cell lung cancer. Mayo Clin. Proc. 83, 355-367 (2008).
12. Forbes, S.A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657 (2010).
13. Pleasance, E.D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2010).
14. Ng, P.C. & Henikoff, S. Accounting for human polymorphisms predicted to affect protein function. Genome Res. 12, 436-446 (2002).
15. Ramensky, V., Bork, P. & Sunyaev, S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30, 3894-3900 (2002).
16. González-Pérez, A. & Lopez-Bigas, N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am. J. Hum. Genet. 88, 440-449 (2011).
17. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
18. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature published online, doi:10.1038/nature11282 (15 August 2012).
19. Molderings, G.J. et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand. J. Gastroenterol. 42, 1045-1053 (2007).
20. D'Angelo, S.P. & Pietanza, M.C. The molecular pathogenesis of small cell lung cancer. Cancer Biol. Ther. 10, 1-10 (2010).
21. Medina, P.P. et al. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum. Mol. Genet. 18, 1343-1352 (2009).
22. Tompkins, D.H. et al. Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS ONE 4, e8248 (2009).
23. Wegner, M. SOX after SOX: SOXession regulates neurogenesis. Genes Dev. 25, 2423-2428 (2011).
24. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
25. Lujan, E., Chanda, S., Ahlenius, H., Sudhof, T.C. & Wernig, M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc. Natl. Acad. Sci. USA 109, 2527-2532 (2012).
26. Bass, A.J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242 (2009).
27. Mäkelä, T.P., Saksela, K., Evan, G. & Alitalo, K. A fusion protein formed by L-myc and a novel gene in SCLC. EMBO J. 10, 1331-1335 (1991).
28. Robinson, D.R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 17, 1646-1651 (2011).
29. Lu, Y. et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS ONE 5, e11022 (2010).
30. Gontan, C. et al. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev. Biol. 317, 296-309 (2008).
31. Sholl, L.M., Long, K.B. & Hornick, J.L. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl. Immunohistochem. Mol. Morphol. 18, 55-61 (2010).
32. Güre, A.O. et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc. Natl. Acad. Sci. USA 97, 4198-4203 (2000).
33. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
34. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
35. Takeuchi, K. et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378-381 (2012).
36. Morgan, M. et al. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics 25, 2607-2608 (2009).
37. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
38. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
39. Sherry, S.T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001).
40. Martincorena, I., Seshasayee, A.S. & Luscombe, N.M. Evidence of non-random mutation rates suggests an evolutionary risk management strategy. Nature 485, 95-98 (2012).
41. Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
42. Greenman, C.D. et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 11, 164-175 (2010).
43. Mermel, C.H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
44. Simms, E., Gazdar, A.F., Abrams, P.G. & Minna, J.D. Growth of human small cell (oat cell) carcinoma of the lung in serum-free growth factor-supplemented medium. Cancer Res. 40, 4356-4363 (1980).
45. Phelps, R.M. et al. NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. Suppl. 24, 32-91 (1996).
46. Carney, D.N., Bepler, G. & Gazdar, A.F. The serum-free establishment and in vitro growth properties of classic and variant small cell lung cancer cell lines. Recent Results Cancer Res. 99, 157-166 (1985).
47. Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
48. Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498-504 (2009).